Darolutamide and survival in metastatic, hormone-sensitive prostate cancer: a plain language summary of the ARASENS trial

Video Journal of Biomedicine | Animated Video
Video Journal of Biomedicine (2022) doi: 10.2217/vjbm-2022-0009

Learn more about the ARASENS trial originally published in the New England Journal of Medicine in this animated video that provides an overview of the plain language summary of publication.

The ARASENS trial looked at the role of darolutamide in the treatment of patients with a type of prostate cancer called metastatic, hormone-sensitive prostate cancer. This plain language summary of publication, published in Future Oncology, provides an overview of this trial written in non-technical language. The summary includes commentary from patients and a caregiver and can help a wider audience, including patient advocates and healthcare professionals, understand the findings from this trial.

Read the plain language summary of publication at https://www.futuremedicine.com/doi/10.2217/fon-2022-0433

Original publications:

Darolutamide and survival in metastatic, hormone-sensitive prostate cancer: a patient and caregiver perspective and plain language summary of the ARASENS trial
Matthew R Smith, Maha Hussain, Fred Saad, Karim Fizazi, Cora N Sternberg, David Crawford, Jan Manarite, David Muslin, Thomas Farrington & Bertrand Tombal
Future Oncology (2022) https://www.futuremedicine.com/doi/10.2217/fon-2022-0433

Darolutamide and survival in metastatic, hormone-sensitive prostate cancer
Matthew R Smith, Maha Hussain, Fred Saad et al. ARASENS Trial Investigators.
New England Journal of Medicine 386(12):1132-1142 (2022). https://www.nejm.org/doi/full/doi: 10.1056/NEJMoa2119115